A detailed history of Two Sigma Investments, LP transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 388,308 shares of PMVP stock, worth $578,578. This represents 0.0% of its overall portfolio holdings.

Number of Shares
388,308
Previous 399,710 2.85%
Holding current value
$578,578
Previous $679,000 7.36%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.51 - $2.21 $17,217 - $25,198
-11,402 Reduced 2.85%
388,308 $629,000
Q1 2024

May 15, 2024

BUY
$1.51 - $3.12 $182,723 - $377,548
121,009 Added 43.42%
399,710 $679,000
Q4 2023

Feb 14, 2024

BUY
$1.23 - $6.6 $300,894 - $1.61 Million
244,630 Added 718.0%
278,701 $863,000
Q3 2023

Nov 14, 2023

SELL
$6.01 - $8.93 $155,923 - $231,679
-25,944 Reduced 43.23%
34,071 $209,000
Q2 2023

Aug 14, 2023

SELL
$3.94 - $6.27 $303,123 - $482,382
-76,935 Reduced 56.18%
60,015 $375,000
Q1 2023

May 15, 2023

BUY
$4.77 - $9.16 $586,471 - $1.13 Million
122,950 Added 878.21%
136,950 $653,000
Q4 2022

Feb 14, 2023

SELL
$8.17 - $12.95 $117,648 - $186,480
-14,400 Reduced 50.7%
14,000 $121,000
Q3 2022

Nov 14, 2022

BUY
$11.4 - $17.18 $323,760 - $487,912
28,400 New
28,400 $338,000
Q2 2022

Aug 15, 2022

SELL
$9.23 - $22.43 $414,427 - $1.01 Million
-44,900 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$14.86 - $23.55 $3.37 Million - $5.34 Million
-226,646 Reduced 83.47%
44,900 $935,000
Q4 2021

Feb 14, 2022

BUY
$19.99 - $30.24 $5.14 Million - $7.77 Million
257,046 Added 1772.73%
271,546 $6.27 Million
Q3 2021

Nov 15, 2021

BUY
$26.84 - $36.58 $389,180 - $530,410
14,500 New
14,500 $432,000

Others Institutions Holding PMVP

About PMV Pharmaceuticals, Inc.


  • Ticker PMVP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,622,600
  • Market Cap $68M
  • Description
  • PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...
More about PMVP
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.